[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353816-105":59,"doc-detail-353816-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","therapeutic-potential-of-fingolimod-and-dimethyl-fumarate-in-preclinical-pancreatic-cancer-models","Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Preclinical Pancreatic Cancer Models","","Pancreatic cancer has a very low five-year survival rate, and current care relying on radiotherapy and chemotherapy—sometimes paired with targeted therapy—offers limited clinical benefit. Fingolimod and dimethyl fumarate (DMF), approved for multiple sclerosis, have shown anti-cancer activity in multiple preclinical tumor systems. This study evaluates their therapeutic potential in pancreatic cancer by testing in vitro cytotoxicity and in vivo antitumor effects using 3D spheroids and xenograft models compared with gemcitabine and erlotinib.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-potential-of-fingolimod-and-dimethyl-fumarate-in-preclinical-pancreatic-cancer-models/353816/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-potential-of-fingolimod-and-dimethyl-fumarate-in-preclinical-pancreatic-cancer-models/353816.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is there a need for new therapeutic strategies in pancreatic cancer?","Question",{"text":112,"@type":113},"The five-year survival rate is notably low, and although standard treatments like radiotherapy and chemotherapy exist, their clinical benefits remain limited due to early progression and micro-metastases.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the study design used to assess fingolimod and DMF?",{"text":117,"@type":113},"The study evaluated in vitro cytotoxicity using 3D spheroid tumor models and in vivo antitumor effects in xenograft models, comparing results with standard-of-care gemcitabine and erlotinib.",{"name":119,"@type":110,"acceptedAnswer":120},"What main outcomes did the study report for fingolimod and DMF?",{"text":121,"@type":113},"Both drugs induced cytotoxicity in spheroids derived from pancreatic cell lines and showed anticancer effects in two subcutaneous xenograft models using PANC-1 and CFPAC-1 cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353816,1791320257,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Tech Science Press  \nDoi:10.32604/or.2025.072141  \nARTICLE  \nTherapeutic Potential ofFingolimod and Dimethyl Fumarate in Preclinical Pancreatic Cancer Models  \nPauline Gousseau\\#, Laurie Genest, Guillaume Froget and Tristan Rupp*,§  \nPorsolt SAS, ZA de Glatigné, Oncology Group, Le Genest-Saint-Isle, 53940, France  \n*Corresponding Author: Tristan Rupp. Email: [rupptristan@hotmail.fr](rupptristan@hotmail.fr)  \n\\# Current address: NEURO-DOL Basics and Clinical Pharmacology of Pain, INSERM—UMR 1107, University of Clermont Auvergne, Clermont-Ferrand, 63000, France  \n§ Lead Corresponding Author  \nReceived: 20 August 2025; Accepted: 29 December 2025; Published: 24 February 2026  \nABSTRACT: Objectives: The five-year survival rate for pancreatic cancer is notably low, posing a significant challenge to patient health. The primary treatments are radiotherapy and chemotherapy, sometimes combined with targeted therapy; however, their clinical benefits are limited. Therefore, developing new models to evaluate the therapeutic potential of novel molecules is essential. Fingolimod and Dimethyl Fumarate (DMF), currently used to treat multiple sclerosis, have recently been shown to have anti-cancer effects in several preclinical tumor models. This study aims to evaluate the therapeutic potential ofFingolimod and DMF in pancreatic cancer by investigating their respective in vitro cytotoxicity and in vivo antitumor effects. Methods: In this study, we evaluated for the first time these two drugs in pancreatic preclinical models in vitro using3D spheroid tumor models and in vivo, which are compared to two standardof-care consisting of Gemcitabine and Erlotinib. Results: In vitro, both Fingolimod and DMF induced cytotoxicityin spheroids from two pancreatic cell lines. Additionally, Fingolimod and DMF displayed anticancer effects in two subcutaneous xenograft models using PANC-1 and CFPAC-1 cells. Conclusions: Although the responses observed with Fingolimod and DMF were similar to those of Gemcitabine and Erlotinib, these findings indicate a potential emerging interest in Fingolimod and DMF for the treatment of pancreatic cancer. However, further work is still necessary to fully characterize how these drugs affect tumor progression.  \nKEYWORDS: Pancreatic cancer; preclinical models; tumor progression; fingolimod; dimethyl Fumarate  \n1 Introduction  \nPancreatic cancer (PC) is a major public health problem worldwide, particularly in developed countries. The 5-year survival rate does not exceed 10%[1] . In 2021, the incidence and mortality rates for PC were 5.96 and 5.94 per 100,000 people, respectively [1] . In 2022, PC ranked as the sixth leading cause of cancerrelated mortality, affecting all demographic groups. By 2030, PC is projected to become the second deadliest cancer worldwide, largely due to ineffective treatment options [2] . Common symptoms include abdominal pain, weight loss, nausea, and fatigue [3] . The tumor can also obstruct the bile ducts, which may impair liver function [4] . While PC tumors develop gradually, often delaying diagnosis, the disease progresses rapidly once symptoms appear [3]. The predominant risk factors are behavioral, including smoking, alcoholism, and obesity; meanwhile, genetic factors account for only 10% of cases [5] .  \nCopyright © 2026 The Authors. Published by Tech Science Press.  \nThis work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nSurgery currently offers the best prognosis for patients without metastases [6] . Unfortunately, only 20% of patients are eligible, as most present with metastatic disease at diagnosis [6]. Radiotherapy is typically used post-surgery to reduce tumor recurrence; it can also be administered pre-surgery to aid tumor resection [6] . For unresectable tumors, radiotherapy is often combined with chemotherapy. Gemcitabine is the sta","cbCaionSQ18tgwln","https://ap.wps.com/l/cbCaionSQ18tgwln","pdf",7041267,"English","# Abstract\n# Keywords\n# 1 Introduction\n## Pancreatic cancer burden and clinical context\n## Current standard-of-care treatments","[{\"question\":\"Why is there a need for new therapeutic strategies in pancreatic cancer?\",\"answer\":\"The five-year survival rate is notably low, and although standard treatments like radiotherapy and chemotherapy exist, their clinical benefits remain limited due to early progression and micro-metastases.\"},{\"question\":\"What was the study design used to assess fingolimod and DMF?\",\"answer\":\"The study evaluated in vitro cytotoxicity using 3D spheroid tumor models and in vivo antitumor effects in xenograft models, comparing results with standard-of-care gemcitabine and erlotinib.\"},{\"question\":\"What main outcomes did the study report for fingolimod and DMF?\",\"answer\":\"Both drugs induced cytotoxicity in spheroids derived from pancreatic cell lines and showed anticancer effects in two subcutaneous xenograft models using PANC-1 and CFPAC-1 cells.\"}]","Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Preclinical Pancreatic Cancer Models | PDF",1790107392,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6bce0217b716982897166084aa10bd2.webp",983,1271,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbc98a4939a97450b6515c5f747facb3.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/777633f13fe1198799f4fe50a3e8c29f.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/016f87b8182bc4bc990d7b1b00c28024.webp",980,1267]